Trial · NCT07460180
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
NCT07460180, Phase 1, Phase 2, Recruiting, The Netherlands Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer. Trials, record NCT07460180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07460180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
- NCT number
- NCT07460180
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 55 participants, estimated
- Lead sponsor
- The Netherlands Cancer Institute
- Conditions
- Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
- Interventions
- Olaparib
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and toxicity of combining PARP-inhibitors with HIPEC | 4 years | Safety lead in phase 1 part: evaluation of dose limiting toxicities by CTCAE v.5 and Clavien dindo from start PARP inhibition until 28 days postoperatively. Evaluated dosages are 100mg, 150mg and 300mg BID of olaparib. Further toxicity will be evaluated in phase 2, in which an additional number of patients will be treated with recommended phase 2 dose. |
| Secondary | The degree of PARP (enzymatic) inhibition | 4 years | Blood and intracellular PARP activity will be measured, and the extent of PARP inhibition will be quantified as percentage reduction (%) from baseline activity levels in all enrolled patients. |
| Other | Overall survival (OS) | 10 years | |
| Other | Recurrence-free survival (RFS) | 10 years | |
| Other | Tumor cell proliferation (Ki67) | 4 years | |
| Other | DNA damage (yH2AX foci assay) | 10 years | |
| Other | ○ Apoptosis (cl-Casp3) | 4 years | |
| Other | Functional homologous recombination (RAD51 foci assay) | 10 years | |
| Other | The establishment of patient-derived organoids/explants cultures from tumor tissue collected intraoperatively | 4 years | Tumor tissue obtained during cytoreductive surgery will be used to generate PDOs and/or short-term explant cultures. These ex vivo models will be used to mimic the cellular response of patient tumors after clinical exposure to PARP inhibitors (PARPi) and HIPEC, allowing evaluation of treatment effects over time. |
| Other | Treatment effects in the tumor microenvironment | 4 years | Spatial proteomics analyses (CODEX) comparing the baseline tumor microenvironment with the on post treatment tumor microenvironment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07460180
GET https://conductscience.org/api/trials/v1/NCT07460180/registered